Amgen (AMGN) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Amgen Inc. (AMGN) insider buying and selling: no purchases, 10 sales
106 Form 4 Table I transactions filed with the SEC by Amgen Inc. insiders between 2025-11-07 and 2026-08-13 (15-month history): 0 open-market purchases and 10 sales, plus 96 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $20.8M by Santos Esteban on 2026-02-26.
Amgen insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Amgen insiders filed 10 sales worth $29.3M on the open market, and no purchases.
The biggest seller was Santos Esteban (EVP, Operations): $20.8M in 1 sale, out of 6 different sellers.
The largest trade of the period was a sale of $20.8M on Feb 26, 2026, by Santos Esteban (EVP, Operations). Form 4 on sec.gov (0000318154-26-000012).
None of the 10 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 4 sales, against 1 in the three before. The latest sale from Aug 13, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Amgen has more sales than 31 of the other 58, ranks 23 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with AMGN's sales, largest first. The full history is in the tool above, already searched.
See all 106 AMGN trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-03-02 | Santos Esteban | EVP, Operations | $20.8M | S — Open-market sale3 Form 4 footnotesF1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer F3 These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-12 | 2025-11-13 | Gordon Murdo | EVP, Global Commercial Ops | $2.3M | S — Open-market sale2 Form 4 footnotesF1 The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-06 | 2026-08-07 | Miller Derek | SVP, Human Resources | $1.6M | S — Open-market sale3 Form 4 footnotesF1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-06 | 2026-08-07 | Grygiel Nancy A. | SVP & CCO | $1.2M | S — Open-market sale2 Form 4 footnotesF1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-20 | 2025-11-21 | Grygiel Nancy A. | SVP & CCO | $1.1M | S — Open-market sale2 Form 4 footnotesF1 The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-11 | 2026-08-13 | Khosla Rachna | SVP, Business Development | $825k | S — Open-market sale | SEC |
| 2026-08-13 | 2026-08-13 | Khosla Rachna | SVP, Business Development | $521k | S — Open-market sale2 Form 4 footnotesF1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-05-04 | 2026-05-05 | Grygiel Nancy A. | SVP & CCO | $400k | S — Open-market sale2 Form 4 footnotesF1 The price reported is an average price of $323.7272 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer F2 These shares include 72 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-02-19 | 2026-02-20 | Busch Matthew C. | VP, Finance & CAO | $376k | S — Open-market saleForm 4 footnoteF1 These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-12 | 2025-11-13 | Khosla Rachna | SVP, Business Development | $299k | S — Open-market sale2 Form 4 footnotesF1 The price reported is an average price. The prices ranged from $336.2219 to $336.30 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-04 | 2026-03-06 | Bradway Robert A | Chairman, CEO and President | $32.0M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-04 | 2026-03-06 | Bradway Robert A | Chairman, CEO and President | $18.7M | M — Option exerciseForm 4 footnoteF1 Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. | SEC |
| 2026-02-26 | 2026-03-02 | Santos Esteban | EVP, Operations | $9.3M | M — Option exercise | SEC |
| 2026-03-16 | 2026-03-18 | Bradway Robert A | Chairman, CEO and President | $7.8M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 2,696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Gordon Murdo | EVP, Global Commercial Ops | $2.5M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 825 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Reese David M | EVP & Chief Technology Officer | $2.2M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Griffith Peter H. | EVP & CFO | $2.1M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Santos Esteban | EVP, Operations | $2.1M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | $2.0M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 659 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-05-02 | 2026-05-05 | Bradway Robert A | Chairman, CEO and President | $1.7M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 These shares include 1,624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Nov 7, 2025 and Aug 13, 2026 there is not one open-market purchase of Amgen Inc.: 10 sales worth $29.3M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Amgen Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 46 | $60.8M |
| A | Grant or award | 42 | $0 |
| S | Open-market sale | 10 | $29.3M |
| M | Option exercise | 6 | $29.9M |
| G | Gift | 2 | $0 |
| Total | Everything filed in the period | 106 | $120.1M |
44 of the 106 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 22 distinct people or entities have filed Amgen Inc. transactions: none bought on the open market and 6 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 6 who sold on the open market (10 sales in all), the three biggest sellers account for $25.7M of the $29.3M: 88% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations | 8 | — | $20.8M (1) | 2026-05-11 |
| Grygiel Nancy A. | SVP & CCO | 11 | — | $2.7M (3) | 2026-08-07 |
| Gordon Murdo | EVP, Global Commercial Ops | 7 | — | $2.3M (1) | 2026-05-11 |
| Khosla Rachna | SVP, Business Development | 11 | — | $1.6M (3) | 2026-08-13 |
| Miller Derek | SVP, Human Resources | 8 | — | $1.6M (1) | 2026-08-07 |
| Busch Matthew C. | VP, Finance & CAO | 9 | — | $376k (1) | 2026-08-12 |
| Bradway Robert A | Chairman, CEO and President | 8 | — | — | 2026-05-11 |
| Reese David M | EVP & Chief Technology Officer | 8 | — | — | 2026-05-11 |
Shown here are the 8 who moved the most money, out of 22. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2026: 0 purchases and 4 sales, worth $4.1M. 11 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 3 | $3.7M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 2 | $21.1M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $400k |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 4 | $4.1M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Amgen Inc. (AMGN) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 10 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Amgen has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Aug 13, 2026, and a Form 4 arrives up to two business days after the trade.
18 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.